Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial

Patnaik A.Yap T.A.Chung H.C.de Miguel M.J.Bang Y.-J.CHIA-CHI LINSu W.-C.Italiano A.Chow K.H.Szpurka A.M.Yu D.Zhao Y.Carlsen M.Schmidt S.Vangerow B.Gandhi L.Xu X.Bendell J.2022-09-152022-09-1520211078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102516128&doi=10.1158%2f1078-0432.CCR-20-2821&partnerID=40&md5=ba3822476b1f62818f86c34f69b9f0cchttps://scholars.lib.ntu.edu.tw/handle/123456789/620221[SDGs]SDG3Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trialjournal article10.1158/1078-0432.CCR-20-2821332294562-s2.0-85102516128